"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo) for HER2-positive breast cancer

FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo) for HER2-positive breast cancer

30 Jun 2020 7:04 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase–zzxf
(PHESGO, Genentech, Inc.) for subcutaneous injection for the following indications: 

  • Use in combination with chemotherapy as: 
    • neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer;
    • adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.
  • Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Read full press release.


Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software